Shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA – Free Report) are going to reverse split on Monday, November 23rd. The 1-15 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, November 22nd.
Lisata Therapeutics Trading Down 1.2%
Shares of LSTA stock traded down $0.01 on Friday, reaching $0.90. The company’s stock had a trading volume of 139,260 shares, compared to its average volume of 184,186. The stock’s fifty day simple moving average is $1.21 and its 200-day simple moving average is $2.79. Lisata Therapeutics has a 1 year low of $0.85 and a 1 year high of $5.07. The company has a market capitalization of $9.71 million, a price-to-earnings ratio of -0.48 and a beta of 1.04.
Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.39. Equities research analysts forecast that Lisata Therapeutics will post -1.09 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Wednesday, November 11th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce”.
Get Our Latest Stock Analysis on Lisata Therapeutics
Institutional Investors Weigh In On Lisata Therapeutics
Several institutional investors have recently made changes to their positions in the company. venBio Partners LLC purchased a new position in shares of Lisata Therapeutics during the 3rd quarter worth about $225,000. Nantahala Capital Management LLC purchased a new stake in Lisata Therapeutics in the 3rd quarter worth about $146,000. Bank of America Corp DE purchased a new stake in Lisata Therapeutics in the 2nd quarter worth about $35,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Lisata Therapeutics in the second quarter worth about $157,000. Finally, BlackRock Inc. purchased a new position in shares of Lisata Therapeutics during the second quarter valued at approximately $187,000. Institutional investors own 8.94% of the company’s stock.
Lisata Therapeutics Company Profile
Lisata Therapeutics is a clinical-stage biopharmaceutical company developing therapies for cancer and other serious diseases. The company’s research focuses on improving the delivery of treatments to solid tumors. Its lead investigational product, certepetide (also known as LSTA1 or CEND-1), is a peptide being studied in combination with existing cancer therapies. Clinical development has included pancreatic cancer and other solid tumors; certepetide is not an approved commercial treatment. Lisata adopted its current name in 2022 following a merger involving Cend Therapeutics and the former Caladrius Biosciences.
Featured Stories
- Five stocks we like better than Lisata Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
